Table 2 Response rates adjusted for stabilized trimmed inverse probability treatment weighting.

From: KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

Responsea

KarMMa cohortb (N = 128)

Eligible RRMM cohort (N = 190)

KarMMa cohort 450 × 106 CAR + T Cells (N = 54)

Eligible RRMM cohort (N = 190)

ORR (95% CI), %

76.4 (67.8–86.1)

32.2 (24.4–42.3)

82.0 (70.3–95.7)

31.4 (25.0–39.4)

 RR (95% CI)

2.4 (1.7–3.3)

2.6 (2.0–3.5)

 P

<0.0001

<0.0001

≥VGPRc rate (95% CI), %

57.9 (47.8–70.1)

13.7 (8.6–21.9)

67.4 (52.6–86.4)

13.5 (9.1–20.1)

 RR (95% CI)

4.2 (2.5–7.2)

5.0 (3.1–8.0)

 P

<0.0001

<0.0001

  1. ORR was defined as percentage of patients who achieved a best response of partial response or better.
  2. ≥VGPR rate was defined as percentage of patients who achieved a best response of VGPR or better.
  3. CI confidence interval, IPTW inverse probability treatment weighting, ORR overall response rate, RR risk ratio, VGPR very good partial response.
  4. aDerived for the KarMMa and Eligible RRMM cohorts using trimmed stabilized inverse probability treatment weighting propensity score.
  5. bAcross all target doses.
  6. cComplete response not reported due to missing biopsy data in the Eligible RRMM cohort to confirm response.
Back to article page